

PhD graduate with strong hands-on experience in LC–MS analysis and characterisation of biopharmaceuticals, including data processing, interpretation and quality assessment. Experienced with mass spectrometry techniques such as intact protein analysis, peptide mapping and DAR determination, alongside recombinant protein expression, purification and FRET-based activity assays. Motivated by collaborative, cross-functional work and by contributing to robust, high-throughput analytical workflows that support biopharmaceutical process and product development to deliver real-world impact.
Industry collaboration with AstraZeneca (Cambridge, England) focused on identification and characterisation of inhibitors of ADAMTS8. This work involves expression and purification of enzyme, followed by FRET-based activity assays to support inhibitor screening and validation. In parallel, I perform LC- and MS-based analytical characterisation of biopharmaceutical candidates, as well as MS analyses such as intact protein analysis and peptide mapping. Strong emphasis on data quality, method robustness and documentation in industry-driven, high-throughput environments.
4-month work experience in one of the leading hospitals of the Middle East which allowed me to acquire first-hand practice and knowledge of the haematology department, from patient sample collection to analysis.
Recipient of the Young Scientist and Best Speaker Award at the 2023 Proteinases and Inhibitors Conference (Tiers, Italy).